Details of the Drug

General Information of Drug (ID: DM7YPM1)

Drug Name
Enfuvirtide
Synonyms Fuzeon; Pentafuside; Enfuvirtide [USAN]; Roche brand of pentafuside; DP178; Dp 178; Peptide T20; T 20; T20 peptide; Fuzeon (TN); T 20 (peptide); T-20; T-20 cpd
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Therapeutic Class
Anti-HIV Agents
Drug Type
Small molecular drug
Sequence
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 5 Molecular Weight (mw) 4565
Topological Polar Surface Area (xlogp) -17.2
Rotatable Bond Count (rotbonds) 154
Hydrogen Bond Donor Count (hbonddonor) 65
Hydrogen Bond Acceptor Count (hbondacc) 70
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.36 mL/min/kg [3]
Elimination
0% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.8 +/- 0.6 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.5724 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.08% [3]
Vd
The volume of distribution (Vd) of drug is 5.5 +/- 1.1 L [5]
Water Solubility
The ability of drug to dissolve in water is measured as 1000 mg/mL [2]
Chemical Identifiers
Formula
C206H304N52O66
IUPAC Name
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-(2-acetylhydrazinyl)-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-amino-4-oxobutanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-(carboxymethylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-oxopentanoic acid
Canonical SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC5=CNC6=CC=CC=C65)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)NCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC8=CN=CN8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC9=CC=C(C=C9)O)NNC(=O)C
InChI
InChI=1S/C206H304N52O66/c1-20-103(15)168(254-197(315)137(75-101(11)12)239-202(320)151(94-261)252-192(310)143(82-113-90-216-96-221-113)249-205(323)169(104(16)21-2)255-198(316)138(76-102(13)14)240-203(321)152(95-262)253-206(324)170(106(18)263)256-199(317)148(258-257-107(19)264)78-109-45-47-114(265)48-46-109)204(322)234-132(58-68-165(283)284)180(298)229-131(57-67-164(281)282)184(302)251-150(93-260)200(318)233-126(52-62-156(212)269)181(299)246-145(84-158(214)271)193(311)230-125(51-61-155(211)268)177(295)225-123(49-59-153(209)266)175(293)227-127(53-63-160(273)274)178(296)223-121(43-31-33-69-207)174(292)245-144(83-157(213)270)194(312)232-128(54-64-161(275)276)179(297)226-124(50-60-154(210)267)176(294)228-129(55-65-162(277)278)182(300)235-134(72-98(5)6)187(305)237-133(71-97(3)4)186(304)231-130(56-66-163(279)280)183(301)236-135(73-99(7)8)189(307)248-147(86-166(285)286)196(314)224-122(44-32-34-70-208)173(291)242-140(79-110-87-217-118-40-28-25-37-115(110)118)185(303)222-105(17)171(289)250-149(92-259)201(319)238-136(74-100(9)10)188(306)243-142(81-112-89-219-120-42-30-27-39-117(112)120)191(309)247-146(85-159(215)272)195(313)244-141(80-111-88-218-119-41-29-26-38-116(111)119)190(308)241-139(172(290)220-91-167(287)288)77-108-35-23-22-24-36-108/h22-30,35-42,45-48,87-90,96-106,121-152,168-170,217-219,258-263,265H,20-21,31-34,43-44,49-86,91-95,207-208H2,1-19H3,(H2,209,266)(H2,210,267)(H2,211,268)(H2,212,269)(H2,213,270)(H2,214,271)(H2,215,272)(H,216,221)(H,220,290)(H,222,303)(H,223,296)(H,224,314)(H,225,295)(H,226,297)(H,227,293)(H,228,294)(H,229,298)(H,230,311)(H,231,304)(H,232,312)(H,233,318)(H,234,322)(H,235,300)(H,236,301)(H,237,305)(H,238,319)(H,239,320)(H,240,321)(H,241,308)(H,242,291)(H,243,306)(H,244,313)(H,245,292)(H,246,299)(H,247,309)(H,248,307)(H,249,323)(H,250,289)(H,251,302)(H,252,310)(H,253,324)(H,254,315)(H,255,316)(H,256,317)(H,257,264)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)/t103-,104-,105-,106+,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,168-,169-,170-/m0/s1
InChIKey
BWVBEUNZTQWGMR-CKVIKZOTSA-N
Cross-matching ID
PubChem CID
24847866
DrugBank ID
DB00109
TTD ID
D06GBQ
INTEDE ID
DR0580

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Glycoprotein 41 (HIV gp41) TTG90S6 ENV_HV1H2 Modulator [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [7]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Enfuvirtide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cobicistat DM6L4H2 Moderate Decreased metabolism of Enfuvirtide caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [34]

References

1 Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect a... J Virol. 2009 Aug;83(16):7862-72.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86.
8 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
9 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
10 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
11 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
12 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
13 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
14 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
15 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
16 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
17 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
18 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
19 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
20 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
21 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
22 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
23 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
24 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
25 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
26 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
27 Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem.2012 Feb 24;287(9):6788-96.
28 Clinical pipeline report, company report or official report of Immunotech Laboratories.
29 HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002 Oct;2(5):523-8.
30 DOI: 10.1038/mt.sj.6300124
31 An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428.
32 Clinical pipeline report, company report or official report of ViiV Healthcare.
33 Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617.
34 Cerner Multum, Inc. "Australian Product Information.".